We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Society for Laboratory Automation and Screening Fully Established

By LabMedica International staff writers
Posted on 04 Aug 2010
On July 1, 2010, after almost two years strategizing, the Society for Biomolecular Sciences (SBS) and the Association for Laboratory Automation (ALA) united as one inclusive organization--the Society for Laboratory Automation and Screening (SLAS; IL, USA).

SBS and ALA will constitute individual sections of SLAS. More...
Each section will continue to pursue its current mission. The current SBS mission is to advance the science and technology of drug discovery and the use and development of biomolecular screening technology.

The current ALA mission is to further science and education related to laboratory automation, and in particular to encourage and advance the study and to improve the practice of laboratory automation.

SBS's and ALA's former identities and specialized educational programs will be preserved. Both will benefit from the expanded scope, international influence, and enhanced program and service offerings that the unified organization, SLAS, will provide.

The Journal for Biomolecular Screening (JBS) and Journal of the Association for Laboratory Automation (JALA) will continue their publishing schedules and immediate educational programs will take place as scheduled.

The CEO of SLAS, Greg Dummer, outlined the new society's aims. "Our objective right now is to be ready for business as a united new entity sometime later this year. With the traditional SBS and ALA conferences and exhibitions set for the first quarter of 2011, we have to maintain a high level of focus and determination; and we must look to appropriately blend some aspects of SLAS into each of these events."

During the transition period, which will take place throughout 2011, the new SLAS board of directors, with the leadership of the SBS and ALA sections will develop the long-range strategy.

The SALS is a not-for-profit corporation organized and operated exclusively for charitable, educational, and scientific purposes. Its aim is to be the preeminent global organization providing forums for education and information exchange pertaining to laboratory automation and screening.

Related Links:

Society for Biomolecular Sciences
Association for Laboratory Automation




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.